VER-01 clinical trials
Also written VER-01.
How each study uses VER-01 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the VER-01 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- VER-01
- 6
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Who runs them
Industry 6 · Other 0
Vertanical GmbH (6)
Studies
Open first, then newest update. How each study uses VER-01 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral RadiculopathyRecruitingPhase 3Vertanical GmbHNCT06956014Written as VER-01
- Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back PainCompletedPhase 2Vertanical GmbHNCT06475001Written as VER-01
- Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back PainCompletedPhase 3Vertanical GmbHNCT05610813Written as VER-01
- Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back PainCompletedPhase 3Vertanical GmbHNCT04940741Written as VER-01
- Food Effect Study of VER-01 in Healthy VolunteersCompletedPhase 1Vertanical GmbHNCT04930796Written as VER-01
- Single and Multiple Dose Study of VER-01 in Healthy VolunteersCompletedPhase 1Vertanical GmbHNCT04930809Written as VER-01